Targeting bone marrow pathway may curb bone loss - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Targeting bone marrow pathway may curb bone loss

Researchers identify a pathway connecting bone marrow fat accumulation, inflammation, and impaired bone formation, with combined treatment preserving skeletal structure in aging mice.

  • By

  • Andrea Surnit

  • October 19, 2026

  • 4 min

Share

  • 1

    STING signaling in bone marrow macrophages progressively increased with age in male mice.

  • 2

    Myeloid-specific STING deletion attenuated bone loss from 10 to 24 months, although bone mass was not significantly different at 24 months.

  • 3

    Macrophage-targeted STING knockdown from 12 to 18 months improved bone mineral density and trabecular measures and reduced marrow adipocyte accumulation.

  • 4

    Combined H-151 and NMN treatment improved bone microarchitecture and bone formation in mice, with changes comparable to those observed with alendronate.

  • 5

    The preclinical findings implicate a DPP4–TLR4–STING–CD38 pathway in age-related marrow changes, but do not establish efficacy or safety in humans.

Original Source(s)

Targeting bone marrow pathway may curb bone loss

  • by Andrea Surnit

  • October 19, 2026

Related Content

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.

An Observational Study of Post-hip Fracture Outcomes in Older Adults with Type 2 Diabetes

Tuberosity refixation in reverse proximal humerus fracture arthroplasty: a prospective cohort study with two-year follow-up